Microbiome, metabolome, and transcriptome analyses in esophageal squamous cell carcinoma: insights into immune modulation by F. nucleatum

Xue Zhang; Jing Han; Yudong Wang; Li Feng; Zhisong Fan; Yu Su; Wenya Song; Lan Wang; Long Wang; Hui Jin; Jiayin Liu; Dan Li; Guiying Li; Yan Liu; Jing Zuo; Zhiyu Ni

doi:10.1093/procel/pwae063

Protein Cell ›› 2025, Vol. 16 ›› Issue (6) : 491 -496. DOI: 10.1093/procel/pwae063

LETTER

Microbiome, metabolome, and transcriptome analyses in esophageal squamous cell carcinoma: insights into immune modulation by F. nucleatum

Author information +

History +

PDF (9203KB)

Cite this article

Download citation ▾

Xue Zhang, Jing Han, Yudong Wang, Li Feng, Zhisong Fan, Yu Su, Wenya Song, Lan Wang, Long Wang, Hui Jin, Jiayin Liu, Dan Li, Guiying Li, Yan Liu, Jing Zuo, Zhiyu Ni. Microbiome, metabolome, and transcriptome analyses in esophageal squamous cell carcinoma: insights into immune modulation by F. nucleatum. Protein Cell, 2025, 16(6): 491-496 DOI:10.1093/procel/pwae063

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Ding N, Cheng Y, Liu H et al. Fusobacterium nucleatum infection induces malignant proliferation of esophageal squamous cell carcinoma cell bys putrescine production. Microbiol Spectr 2023;11:e0275922.

[2]	Doki Y, Ajani JA, Kato K et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022;386:449–462.

[3]	Gao L, Xu T, Huang G et al. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell 2018;9:488–500.

[4]	He Y, Fu L, Li Y et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab 2021;33:988–1000.e7.

[5]	Lo CH, Kwon S, Wang L et al. Periodontal disease, tooth loss, and risk of oesophageal and gastric adenocarcinoma: a prospective study. Gut 2021;70:620–621.

[6]	Mager LF, Burkhard R, Pett N et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 2020;369:1481–1489.

[7]	Matson V, Fessler J, Bao R et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104–108.

[8]	Siegel RL, Miller KD, Fuchs HE et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33.

[9]	Sun JM, Shen L, Shah MA et al. KEYNOTE-590 Investigators et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021;398:759–771.

[10]	Wang H, Rong X, Zhao G et al. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metab 2022;34:581–594.e8.

[11]	Wu H, Leng X, Liu Q et al. Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma. Cancer Res 2023;83:3131–3144.

[12]	Yamamura K, Baba Y, Nakagawa S et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res 2016;22:5574–5581.

[13]	Zuo J, Liu Y, Lv W et al. The host microbiota is associated with the occurrence and development of esophageal squamous cell carcinoma. Protein Cell 2023;14:294–298.